Adderall News and Research

RSS
Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Supernus secures $42M through two transactions

Supernus secures $42M through two transactions

FDA notes shortage of ADHD medicines

FDA notes shortage of ADHD medicines

MTF survey shows large decline in teen smoking

MTF survey shows large decline in teen smoking

Attention deficit drugs safe for adult hearts as well

Attention deficit drugs safe for adult hearts as well

ADHD drugs not bad for the heart: Study

ADHD drugs not bad for the heart: Study

ADHD drugs don’t raise risk for heart attacks or stroke: Study

ADHD drugs don’t raise risk for heart attacks or stroke: Study

ADHD medications do not increase risk of heart attack in children, young adults

ADHD medications do not increase risk of heart attack in children, young adults

Stimulant prescription use for ADHD has increased steadily from 1996-2008

Stimulant prescription use for ADHD has increased steadily from 1996-2008

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Rhabdomyolysis episode at University of Iowa signals a public health crisis

Rhabdomyolysis episode at University of Iowa signals a public health crisis

Study finds increased prescription drug abuse among teens

Study finds increased prescription drug abuse among teens

ADHD drug market will decrease from $5 billion in 2009 to $4.1 billion in 2019: Report

ADHD drug market will decrease from $5 billion in 2009 to $4.1 billion in 2019: Report

Impax third quarter net income increases from $6.7 million to $75.2 million

Impax third quarter net income increases from $6.7 million to $75.2 million

Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Impax initiates litigation against Shire over supply of generic Adderall XR

Impax initiates litigation against Shire over supply of generic Adderall XR

USN-DAAT to collect unused, expired prescription and OTC drugs from public

USN-DAAT to collect unused, expired prescription and OTC drugs from public

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults